Master Who Might Be Scared Of histone deacetylase inhibitor IEM 1754

As the mechanism of interaction amongst HGF/c MET and resistance histone deacetylase inhibitor remains unclear, additional exploration into crosstalk and balance amongst these two signal pathways remains vital and needed for the advancement of novel anticancer therapies.

On the other hand, exploration has also shown that cultured cell lines containing the same EGFR genetic lesions present in human tumors can undergo cell cycle arrest or apoptosis when subjected histone deacetylase inhibitor to EGFR inhibition, even under otherwise optimal conditions. This phenomenon, termed oncogene addiction, applies to all clinical scenarios in which cancer cells appear to depend on a single overactive oncogene for their proliferation and survival. For c MET, further consideration needs to be given to the fact that genetic alterations of the kinase can induce oncogene addiction and therefore possibly aid prediction of therapeutic responsiveness. Importantly, research from Comoglio and colleagues has highlighted that preclinical investigations of developmental c MET inhibitors appear to utilize a vast array of differing cell lines, most of which tend not to be genetically characterized.

In order to identity potentially responsive tumors, PARP the different roles that cMET can play in malignant transformation and progression warrant further research. The prevalence of HGF/c MET pathway activation in human malignancies has driven a rapid growth in cancer drug development programs, with several new drugs targeting c MET showing great promise. Several c MET inhibitors are now under evaluation in clinical trials, and the interest around these compounds has consistently increased since an interaction between EGFR and c MET was observed. Clinical trials with these agents will hopefully validate positive observations from preclinical studies. c MET inhibitor agents under development include compounds that directly inhibit HGF and/or its binding to c MET, antibodies targeted at c MET, and small molecule c MET TKIs.

Although traditional drug development has involved a compound to trial process, there is increasing evidence that this should now change to a biology to trial approach, starting with IEM 1754 unraveling of the fundamental mechanisms of cancer targets, which may then drive initial drug discovery and subsequent clinical studies.